Erythropoiesis and iron

Best Practice and Research: Clinical Haematology

Volumn 15, Issue 2, 2002, Pages 399-409

  Cavill, I ^a  

^a CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

Anaemia, diagnosis; Anaemia, iron defficiency; Anaemia, of chronic disease; Erythropoiesis; Erythropoietin; Red blood cells; Reticulocytes

Indexed keywords

ANTIBODY; CYANOCOBALAMIN; CYTOKINE; DNA; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; FERRIC HYDROXIDE SUCROSE; FERRITIN; FOLIC ACID; HEMOGLOBIN; HORMONE ANTIBODY; IRON; IRON DEXTRAN; PHOSPHATE BINDING AGENT; RECOMBINANT ERYTHROPOIETIN; RNA; TRANSFERRIN; ERYTHROPOIETIN ANTIBODY; FERROUS GLUCONATE; HEME; UNCLASSIFIED DRUG;

ANAPHYLAXIS; BONE MARROW; CELL DESTRUCTION; CONTROLLED STUDY; DRUG ADMINISTRATION; DRUG EFFICACY; ERYTHROBLAST; ERYTHROCYTE; ERYTHROID CELL; ERYTHROPOIESIS; FEMALE; FERRITIN BLOOD LEVEL; HORMONAL REGULATION; HUMAN; IRON DEFICIENCY ANEMIA; IRON METABOLISM; IRON STORAGE; MALE; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; IMMUNOLOGY; METABOLISM; PHYSIOLOGY; ANEMIA; CELL PROLIFERATION; DISEASE ASSOCIATION; HEME SYNTHESIS; HEMOGLOBIN DETERMINATION; INFECTION; IRON ABSORPTION; IRON BALANCE; IRON THERAPY; PROTEIN SECRETION; PROTEIN SYNTHESIS; RETICULOCYTE; RHEUMATOID ARTHRITIS; THALASSEMIA; TRANSFERRIN BLOOD LEVEL;

ANEMIA, HYPOCHROMIC; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN; HEMOGLOBINS; HUMANS; IRON;

EID: 0036431572     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1521-6926(02)90004-6     Document Type: Review

References (45)

1. Vaisman B, Meyron-Holtz EG, Fibach E et al. Ferritin expression in maturing normal human erythroid precursors. British Journal of Haematology 2000; 110: 394-401.
2. Hodgetts J, Hoy TG & Jacobs A. Iron uptake and ferritin synthesis in human erythroblasts. Clinical Science 1986; 70: 53-57.
3. Feelders RA, Kuiperkramer EPA & Vaneijk HG. Structure, function and clinical significance of transferrin receptors. Clinical Chemistry and Laboratory Medicine 1999; 37: 1-10.
4. Cavill I, Jacobs A & Worwood M. Diagnostic methods for iron status. Annals of Clinical Biochemistry 1986; 23: 168-171.
5. Cavill I & Ricketts C. Human iron kinetics. In Jacobs A & Worwood M (eds) Iron in Biochemistry and Medicine vol II pp. 573-604. London: Academic Press, 1980.
6. Erslev AJ. Humeral regulation of red cell production. Blood 1953; 8: 349-357.
7. Kurtz A, Eckardt K-U, Tannarhill L & Bauer C. Regulation of erythropoietin production. Contributions to Nephrology 1988; 66: 1-15.
8. D'Andrea A & Zon P. Erythropoietin receptor: subunit structure and activation. Journal of Clinical Investigation 1990; 86: 681-687.
9. Kendall RG. Erythropoietin. Clinical and Laboratory Haematology 2001; 23: 71-80.
10. Cavill I & Ricketts C. The kinetics of iron metabolism. In Jacobs A & Worwood M (eds) Iron in Biochemistry and Medicine. pp. 613-647. London: Academic Press, 1974.
11. Cavill I. Plasma clearance studies. In Lewis SM & Bayley RJ (eds) Radionuclides in Haematology pp. 214-244. Edinburgh: Churchill Livingstone, 1986.
12. Cavill I. The rejected reticulocyte. British Journal of Haematology 1993; 84: 563-565.
13. Al-Adhadh A & Cavill I. Assessment of cellularity in bone marrow fragments. Journal of Clinical Pathology 1983; 36: 176-179.
14. Cavill I & Coles GA. Erythropoiesis in the anaemia of chronic renal failure. Nephrology, Dialysis, Transplantation 1986; 1: 170-174.
15. Basta SS, Soekirman MS, Karyadi D & Scrimshaw NS. Iron deficiency anaemia and the productivity of adult males in Indonesia. American Journal of Clinical Nutrition 1979; 32: 916-925.
16. Vogelzang NJ, Breitbart W, Cella D et al. Patient, care giver and oncologist perceptions of cancer related fatigue: results of a tripartate assessment survey. Seminars in Hematology 1997; 34 (supplement 2): 4-12.
17. Glaspy J, Bukowski R, Steinberg D et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with non-myeloid malignancies during cancer chemotherapy in community oncology practice Journal of Clinical Oncology 1997; 15: 1218-1234.
18. Grogan M, Thomas GM & Melamed I. The importance of haemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999; 86: 1528-1536.
19. Rushton DH, Dover R, Sainsbury AW et al. Why should women have lower reference limits for haemoglobin and ferritin concentrations than men? British Medical Journal 2001; 322: 1355-1357.
20. Stohlman F. Some aspects of erythrokinetics. Seminars in Haematology 1967; 4: 304-314.
21. Jacobs A. Iron deficiency anaemia. In Jacobs A & Worwood M (eds) Iron in Biochemistry and Medicine pp. 405-436. London: Academic Press, 1974.
22. Beamish MR, Davies AG, Eakins JD et al. The measurement of reticulo-endothelial iron release using iron dextran. British Journal of Haematology 1971; 21: 617-622.
23. Kanakorn K, Cavill I & Jacobs A. The metabolism of intravenously administered iron dextran. British Journal of Haematology 1973; 25: 637-643.
24. Stefanelli M, Bentley DP, Cavill I & Roeser HP. Quantitation of reticulo-endothelial iron kinetics in humans. American Journal of Physiology 1984; 247: R842-R849.
25. Bentley DP & Williams P. Parental iron therapy in the anaemia of rheumatoid arthritis. Rheumatology and Rehabilitation 1982; 21: 88-92.
26. Kaltwasser JP, Kessler U, Gottschalk R et al. Effect of recombinant human erythropoietin and intravenous iron on anaemia and disease activity in rheumatoid arthritis. Journal of Rheumatology 2001; 28: 2430-2436.
27. Linkesch W. Ferrochelatase activity in rheumatoid arthritis. In Meeting of the International Society of Haematology pp. Paris: 1978.
28. Fitzsimmons EJ. Abnormal haem biosynthesis in chronic anaemia of rheumatoid arthritis. Annals of the Rheumatic Diseases 1994; 53: 167-170.
29. Harrison PM & Arosio P. Ferritins: molecular properties, iron storage function and cellular regulation. Bba-Bioenergetics 1996; 1275: 161-203.
30. Worwood M. Ferritin. Blood Reviews 1990; 4: 259-269.
31. Cazzola M & Beguin Y. New tools for clinical evaluation of erythron function in man. British Journal of Haematology 1992; 80: 278-284.
32. Punnonen K, Irjala K & Rajamaki A. Serum transferrin receptor and its ratio to serum ferritin in the diagnosis of iron deficiency. Blood 1997; 89: 1052-1057.
33. Malope BI, MacPhail AP, Alberts M & Hiss DC. The ratio of serum transferrin receptor and serum ferritin in the diagnosis of iron status. British Journal of Haematology 2001; 115: 84-89.
34. Winearls CG, Oliver DO, Pippard MJ et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 1986; ii: 1175-1178.
35. Eschbach JW, Egrie JC, Downing MR et al. Correction of end stage renal disease with recombinant human erythropoietin. New England Journal of Medicine 1987; 316: 73-78.
36. Macdougall IC, Hutton RD, Cavill I et al. Treating renal anaemia with recombinant human erythropoietin: practical guidelines and a clinical logarithm. British Medical Journal 1990; 300: 655-659.
37. Eknoyan G. The importance of early treatment of the anaemia of chronic kidney disease. Nephrology, Dialysis, Transplantation 2001; 16: S45-S49.
38. Eschbach JW, Downing MR, Egrie JC et al. USA Multicenter Clinical Trial with recombinant human erythropoietin. Contributions to Nephrology 1989; 76: 160-165.
39. Macdougall IC, Cavill I, Hulme B et al. Detection of functional iron deficiency during erythropoietin treatment: a new approach. British Medical Journal 1992; 304: 225-226.
40. Macdougall IC, Chandler G, Elston O & Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a haemodialysis unit. American Journal of Kidney Diseases 1999; 34: S40-S46.
41. Casadevall N, Nataf J, Viron B et al. Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant human erythropoietin. New England Journal of Medicine 2002; 346: 469-475.
42. Gazal H. Successful treatment of pure red cell aplasia with rituximab in patients with chronic lymphocytic leukaemia. Blood 2002; 99: 1092-1094.
43. Auner HW, Wolfler A, Beham-Schmid C et al. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired pure red-cell aplasia refractory to conventional treatment. British Journal of Haematology 2002; 116: 727-728.
44. van Wyck DB, Cavallo G, Spinowitz BS et al. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American Clinical Trial. American Journal of Kidney Diseases 2000; 36: 88-97.
45. Phillips I. Reticulocyte Indices: New Measurements in Normal and Iron Deficient Erythropoiesis. MSc thesis University of Wales Institute Cardiff UK, 1994.